Enterprise Value
1.345B
Cash
350.4M
Avg Qtr Burn
-35.86M
Short % of Float
7.61%
Insider Ownership
2.61%
Institutional Own.
96.29%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Atrasentan Details Kidney disease, Glomerular diseases, IgA nephropathy Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Atrasentan Details Glomerular diseases, Kidney disease | Phase 2 Interim update | |
BION-1301 (Zigakibart) Details IgA nephropathy | Phase 1/2 Data readout | |
CHK-336 Details Primary hyperoxaluria | Phase 1 Data readout |